Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of Plant-Derived rPA Anthrax Vaccine in Healthy Adults
NCT02239172Phase 1Completed
- Sponsor
- Fraunhofer-Gesellschaft
- Start
- Aug 2014
- Primary completion
- May 2015
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, single-blind trial of PA83-FhCMB in anthrax (4 arms), sponsored by Fraunhofer-Gesellschaft. Primary endpoint: Number of Participants with Adverse Events up to 3 months. Started Aug 2014; status: completed.
02
Drugs
PA83-FhCMB
03
Conditions
anthrax
Beyond the preview
Go deeper on NCT02239172.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02239172.